quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 5, 2025

Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy?

View original at finance.yahoo.com
Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy? Shares of Bank of America BAC, the second-largest U.S. bank, are poised for another year of double-digit gains, building on its strong 30.5% rally in 2024…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Citigroup expects NII (excluding Markets) to grow 5.5% for 2025

    80% confidence

  • Bank of America carries a Zacks Rank #2 (Buy)

    80% confidence

  • Bank of America aims to achieve earnings growth of almost 12% in the medium term

    80% confidence

  • Bank of America targets mid-single-digit CAGR in IB fees and a 50 to 100-bp market share gain over the medium term

    80% confidence

  • Zacks Consensus Estimate for 2026 earnings per share is $4.35

    80% confidence

  • JPMorgan anticipates 2025 NII to be $95.8 billion, up more than 3% year over year

    80% confidence

  • Bank of America targets a 55-59% efficiency ratio

    80% confidence

  • Bank of America projects a 5-7% year-over-year increase in NII for 2026, after similar growth this year

    80% confidence

  • Zacks Consensus Estimate for 2025 earnings per share is $3.80

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com